Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
September-2014 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September-2014 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro

  • Authors:
    • Hong‑Fang Jiang
    • Zhuo Wu
    • Xue Bai
    • Yi Zhang
    • Ping He
  • View Affiliations / Copyright

    Affiliations: Department of Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
  • Pages: 1139-1142
    |
    Published online on: June 30, 2014
       https://doi.org/10.3892/ol.2014.2296
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Daphnoretin is an active constituent of Wikstroemia indica C.A. Mey., which is widely distributed in the northwest and southwest regions of China. Previous studies have shown that daphnoretin has anticancer effects on leukemia, osteosarcoma and uterine cervix cancer cells. However, the effect of daphnoretin on human lung cancer cells has yet to be elucidated. In the present study, daphnoretin was observed to inhibit A549 lung cancer cell proliferation in a concentration‑ and time‑dependent manner. Fluorescent microscopy and flow cytometric analysis showed that daphnoretin induced A549 cell apoptosis in a concentration‑dependent manner. Western blot analysis also revealed that daphnoretin induced apoptosis through the regulation of the B‑cell lymphoma‑2 gene family in A549 cells. These findings indicate that daphnoretin may have potential as a therapeutic agent for the management of lung cancer.

Introduction

Lung cancer is one of the most frequently diagnosed types of cancer and the leading cause of cancer-associated mortality worldwide (1). Despite the development and use of multimodality therapies, including surgery, radiotherapy, conventional chemotherapy and molecular targeted therapy, the clinical outcome of lung cancer treatment remains unsatisfactory, with a five-year overall survival rate of <15% (2). This may be, at least in part, due to the side-effects associated with currently available chemotherapeutic drugs and the resistance of advanced lung cancer (3). Therefore, novel, effective chemotherapeutic agents are required, particularly those that are derived from natural products due to their intrinsic advantages (4–6).

Daphnoretin (Fig. 1) is an active constituent of Wikstroemia indica C.A. Mey. which belongs to the Thymelaceae family and is widely distributed throughout the northwest and southwest regions of China. The root of this plant is used as a remedy for arthritis, tuberculosis, syphilis and pertussis (7). Previous studies have shown that daphnoretin has a number of biological activities, including antifungal effects (8), as well as the inhibition of various sites involved in DNA synthesis (9), the activation of protein kinase C in platelet aggregation (7,10), an antiviral effect on hepatitis B (11) and respiratory syncytial virus properties (12). Furthermore, the anticancer effect of daphnoretin has been reported in various studies (13–15). Such studies have shown that daphnoretin exerts its anticancer effects through the inhibition of cancer cell proliferation, the induction of G2/M-phase arrest and apoptosis. However, the effect of daphnoretin on human lung cancer cells has yet to be elucidated.

Figure 1

Structure of daphnoretin.

The present study aimed to investigate the effect of daphnoretin on the growth of A549 lung cancer cells and the cellular mechanism involved in daphnoretin-induced apoptosis. The findings of the present study suggest that daphnoretin may have potential as an anticancer agent for lung cancer therapy.

Materials and methods

Reagents and chemicals

Daphnoretin was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and a 1-mmol/l stock solution of daphnoretin was prepared in dimethyl sulfoxide (DMSO) and stored at −20°C. Deionized water was used in all of the experiments. Fetal bovine serum (FBS) was purchased from Solarbio Science and Technology Co., Ltd. (Beijing, China), and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Hoechst 33342 and DMSO were purchased from Sigma-Aldrich (St. Louis, MO, USA). An Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) double-staining kit was purchased from KeyGene Inc. (Nanjing, China). Mouse monoclonal anti-human, anti-mouse and anti-rat antibodies against Bcl-2-associated X protein (Bax) (catalogue number, sc-23959), B-cell lymphoma (Bcl)-2 (catalogue number, sc-7382) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; catalogue number, sc-365062) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The secondary polyclonal horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies were also obtained from Santa Cruz Biotechnology, Inc. All other reagents were obtained from Sinopharm Chemical Reagent Co., Ltd. (Shenyang, China).

Cell culture

The A549 human lung cancer cell line was obtained from the China Center for Type Culture Collection (Wuhan, China) and maintained in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2.

MTT assay

The effect of daphnoretin on the proliferation of A549 cells was measured using MTT assay. In brief, A549 cells were plated at a density of 1×104 cells per well on 96-well plates overnight, then treated with various concentrations of daphnoretin (0, 5, 10, 15 and 20 μmol/l) for 24 and 48 h. A total of 20 μl MTT solution [2 mg/ml in phosphate-buffered saline (PBS)] was added to each well and the cells were cultured for 4 h at 37°C. The medium was then removed and 150 μl DMSO was added to solubilize the MTT formazan crystals. The plates were then agitated and the optical density was determined at 570 nm using an ELISA plate reader (Model 550; Bio-Rad Laboratories, Inc., Hercules, CA, USA). At least three independent experiments were performed.

Fluorescence microscopy

A549 cells (1×106) were seeded on six-well plates overnight, then treated with different concentrations of daphnoretin (0 and 10 μmol/l) for 24 h. The cells were washed twice with cold PBS, fixed with cold methanol and acetic acid (3/1, v/v) for 30 min and then stained with Hoechst 33342 (1 mg/ml) for 30 min in the dark. The stained cells were observed using a fluorescence microscope (magnification, ×400; Nikon E800; Nikon Corporation, Tokyo, Japan).

Flow cytometric analysis

The apoptotic rates of the A549 cells were determined using flow cytometric analysis using an Annexin V-FITC apoptosis kit. In brief, A549 cells (1×106) were seeded on six-well plates overnight, then treated with various concentrations of daphnoretin (0, 5, 10 and 15 μmol/l) for 24 h. Cells (1×106) were then harvested using centrifugation (326 × g) for 5 min and washed twice with cold PBS. Staining was performed according to the manufacturer’s instructions (KeyGene Inc.) and the cells were analyzed using a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA). At least three independent experiments were performed.

Western blot analysis

The expression of apoptosis-related proteins was assessed using western blot analysis. In brief, A549 cells (1×106) were seeded on six-well plates overnight, then treated with various concentrations of daphnoretin (0, 5, 10 and 15 μmol/l). Following treatment for 24 h, the total proteins were solubilized and extracted using lysis buffer (20 mM HEPES, pH 7.9, 20% glycerol, 200 mM KCl, 0.5 mM EDTA, 0.5% NP-40, 0.5 mM dithiothreitol and 1% protease inhibitor cocktail). The protein concentration was determined using a bicinchoninic acid protein assay. All samples were separated using SDS-PAGE to determine the protein expression of Bax, Bcl-2 and GAPDH. Blots were developed using an enhanced chemiluminescence kit.

Statistical analysis

Statistical analyses were performed using the SPSS 13.0 package (SPSS, Inc., Chicago, IL, USA). All experiments were performed at least three times. All data are expressed as the mean ± standard deviation. The statistical correlations of the data were tested for significance using analysis of variance and the Student’s t-test. P<0.05 and P<0.01 were considered to indicate statistically significant differences.

Results

Daphnoretin inhibits A549 cell proliferation

To investigate the growth-inhibiting effect of daphnoretin, A549 cells were treated with various concentrations of A549 for 24 and 48 h, and the rate of inhibition was determined using MTT assay. As shown in Fig. 2, A549 cell growth was observed to be inhibited in a concentration- and time-dependent manner.

Figure 2

Proliferation-inhibiting effects of daphnoretin on A549 lung cancer cells. *P<0.05 and **P<0.01, vs. the respective control group.

Daphnoretin induces A549 cell apoptosis

To investigate the apoptosis-inducing effect of daphnoretin, A549 cells were treated with various concentrations of daphnoretin. Following treatment with daphnoretin (0 and 10 μmol/l) for 24 h, cells were analyzed using fluorescent microscopy with Hoechst 33324 staining. As shown in Fig. 3, chromatin condensation, nuclear fragmentation and apoptotic bodies were observed in the treated cells. The results revealed that when exposed to daphnoretin, A549 cells underwent the typical morphological changes that are associated with apoptosis.

Figure 3

Cell apoptosis observed using Hoechst 33342 staining. A549 cells were treated with daphnoretin (0 or 10 μmol/l) for 24 h. The apoptotic cells exhibited chromatin condensation, nuclear fragmentation and apoptotic bodies.

The ratio of apoptotic cells induced by daphnoretin was measured using flow cytometry. A549 cells were treated with various concentrations of daphnoretin (0, 5, 10 and 15 μmol/l) for 24 h and analyzed using flow cytometry with Annexin V and PI staining. As shown in Fig. 4, the ratio of early and late apoptotic cells was observed to be significantly increased in the daphnoretin-treated cells compared with the cells in the control group. The results show that when treated with daphnoretin for 24 h, the ratio of apoptotic cells significantly increased in a concentration-dependent manner.

Figure 4

(A) Daphnoretin-induced apoptosis in A549 cells detected using flow cytometry. A549 cells were treated with daphnoretin (0, 5, 10 and 15 μmol/l) for 24 h. The cells were then harvested and stained with Annexin V and PI and flow cytometric analysis was performed to analyze apoptosis. (B) Summary of the apoptosis data. *P<0.05 and **P<0.01, vs. the respective control group. AV, avidin; FITC, fluorescein isothiocyanate; PI, ßpropidium iodide.

Effect of daphnoretin on Bcl-2 family gene expression

The expression of apoptosis-related proteins was assessed using western blot analysis. As shown in Fig. 5, daphnoretin treatment induced an increase in Bax protein expression and a reduction in Bcl-2 protein expression compared with the control cells. The ratio of Bax to Bcl-2 was observed to increase in a concentration-dependent manner.

Figure 5

Effect of daphnoretin on Bcl-2 family protein expression detected using western blot analysis. A549 cells were treated with daphnoretin (0, 5, 10 and 15 μmol/l) for 24 h. Proteins were then extracted and Bax, Bcl-2 and GAPDH expression were analyzed using western blot analysis. Bcl, B-cell lymphoma; Bax, Bcl-2-associated X protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Discussion

Increasing research attention has been focused on phytochemicals in the search for novel anticancer agents with enhanced efficacy to cancer cells and reduced toxicity to normal cells. Daphnoretin, isolated from Wikstroemia indica C.A. Mey. (16) as well as Daphne mezereum L. and Daphne cannabina Wall. (17), have been shown to induce cell cycle arrest and apoptosis in leukemia, osteosarcoma and HeLa cells (13–15). These findings suggest that daphnoretin may have potential as a novel anti-cancer agent.

In the present study, the results demonstrated that daphnoretin inhibited the growth of A549 lung cancer cells in a concentration- and time-dependent manner. A549 cells treated with daphnoretin exhibited typical apoptotic characteristics, including cytoplasmic shrinkage, plasma membrane blebbing, nuclear chromatin condensation, chromosomal DNA cleavage and fragmentation of the cells into membrane-enclosed vesicles or apoptotic bodies. Flow cytometric analysis revealed that daphnoretin induced A549 cell apoptosis in a concentration-dependent manner. Moreover, Bax/Bcl-2 were found to be involved in the molecular mechanism of daphnoretin-induced apoptosis in A549 cells.

Apoptosis is a type of programmed cell death which occurs through the activation of intrinsic cell suicide pathways (18). Apoptosis is a hallmark of anticancer drug-induced cell death (19). Proteins of the Bcl-2 family are key regulators of the apoptotic pathway (20,21). The Bcl-2 gene family, which is significantly involved in the regulation of cell apoptosis, includes anti-apoptotic genes, including Bcl-2 and Bcl-extra large and pro-apoptotic genes including, Bax, Bcl2-antagonist/killer, Bcl-2-interacting killer, BH3 interacting-domain death agonist and Bcl2-associated agonist of cell death (22,23). Certain traditional Chinese anticancer drugs have been found to induce cell apoptosis through targeting the proteins of the Bcl-2 family and the ratio of Bax/Bcl-2 (24,25). In the present study, western blot analysis revealed that the daphnoretin-induced apoptosis in the A549 cells was mediated through the downregulation of Bcl-2 protein expression and the upregulation of Bax protein expression.

In conclusion, the present study has demonstrated that daphnoretin is capable of inhibiting proliferation and promoting apoptosis in A549 lung cancer cells. Furthermore, this apoptotic response is associated with the regulation of the expression of the Bcl-2 gene family. These findings indicate that daphnoretin may have potential as a therapeutic agent for the management of lung cancer.

Acknowledgements

The present study was supported by the Outstanding Scientific Fund of Shengjing Hospital (grant no. 201205).

References

1 

Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 13:790–801. 2012.

2 

Erridge SC, Møller H, Price A and Brewster D: International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol. 4:570–577. 2007.

3 

Li S, Bao P, Li Z, et al: Inhibition of proliferation and apoptosis induced by a Na+/H+ exchanger-1 (NHE-1) antisense gene on drug-resistant human small cell lung cancer cells. Oncol Rep. 21:1243–1249. 2009.

4 

Hsu SC, Ou CC, Chuang TC, et al: Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo. Cancer Lett. 281:108–116. 2009.

5 

Su CC and Lin YH: Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. Int J Mol Med. 22:847–851. 2008.

6 

Carter BZ, Mak DH, Schober WD, et al: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 111:3742–3750. 2008.

7 

Ko FN, Chang YL, Kuo YH, Lin YL and Teng CM: Daphnoretin, a new protein kinase C activator isolated from Wikstroemia indica C.A. Mey. Biochem J. 295:321–327. 1993.

8 

Hu K, Kobayashi H, Dong A, Iwasaki S and Yao X: Antifungal, antimitotic and anti-HIV-1 agents from the roots of Wikstroemia indica. Planta Med. 66:564–567. 2000.

9 

Hall IH, Tagahara K and Lee KH: Antitumor agents LIII: The effects of daphnoretin on nucleic acid and protein synthesis of Ehrlich ascites tumor cells. J Pharm Sci. 71:741–744. 1982.

10 

Wang JP, Raung SL, Kuo YH and Teng CM: Daphnoretin-induced respiratory burst in rat neutrophils is, probably, mainly through protein kinase C activation. Eur J Pharmacol. 288:341–348. 1995.

11 

Chen HC, Chou CK, Kuo YH and Yeh SF: Identification of a protein kinase C (PKC) activator, daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells. Biochem Pharmacol. 52:1025–1032. 1996.

12 

Ho WS, Xue JY, Sun SS, Ooi VE and Li YL: Antiviral activity of daphnoretin isolated from Wikstroemia indica. Phytother Res. 24:657–661. 2010.

13 

Lee KH, Tagahara K, Suzuki H, et al: Antitumor agents. 49 tricin, kaempferol-3-O-beta-D-glucopyranoside and (+)-nortrachelogenin, antileukemic principles from Wikstroemia indica. J Nat Prod. 44:530–535. 1981.

14 

Gu S and He J: Daphnoretin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Molecules. 17:598–612. 2012.

15 

Yang ZY, Kan JT, Cheng ZY, et al: Daphnoretin-induced apoptosis in HeLa cells: a possible mitochondria-dependent pathway. Cytotechnology. 66:51–61. 2014.

16 

Chen CC, Lin YC, Chen YP and Hsu HYJ: A study on the constituents of Wikstroemia indica C.A. Mey. Taiwan Pharm Assoc. 33:28–29. 1981.

17 

Majumder PL and Sengupta GCJ: Chemical Investigation of Daphne cannabina Wall. J Indian Chem Soc. 45:1058–1062. 1968.

18 

Xiao R, Ferry AL and Dupont-Versteegden EE: Cell death-resistance of differentiated myotubes is associated with enhanced anti-apoptotic mechanisms compared to myoblasts. Apoptosis. 16:221–234. 2011.

19 

Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011.

20 

Jendrossek V: The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol. 13:1426–1438. 2012.

21 

Ott M, Norberg E, Zhivotovsky B and Orrenius S: Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ. 16:1075–1082. 2009.

22 

Robertson JD and Orrenius S: Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol. 30:609–627. 2000.

23 

Tamm I, Schriever F and Dörken B: Apoptosis: implications of basic research for clinical oncology. Lancet Oncol. 2:33–42. 2001.

24 

Li SG, Wang YY, Ye ZY, et al: Proliferative and apoptotic effects of andrographolide on the BGC-823 human gastric cancer cell line. Chin Med J (Engl). 126:3739–3744. 2013.

25 

Yu J, Zhou X, He X, Dai M and Zhang Q: Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC-7721 cells. Asian Pac J Cancer Prev. 12:1925–1929. 2011.

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Jiang HF, Wu Z, Bai X, Zhang Y and He P: Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro. Oncol Lett 8: 1139-1142, 2014.
APA
Jiang, H., Wu, Z., Bai, X., Zhang, Y., & He, P. (2014). Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro. Oncology Letters, 8, 1139-1142. https://doi.org/10.3892/ol.2014.2296
MLA
Jiang, H., Wu, Z., Bai, X., Zhang, Y., He, P."Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro". Oncology Letters 8.3 (2014): 1139-1142.
Chicago
Jiang, H., Wu, Z., Bai, X., Zhang, Y., He, P."Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro". Oncology Letters 8, no. 3 (2014): 1139-1142. https://doi.org/10.3892/ol.2014.2296
Copy and paste a formatted citation
x
Spandidos Publications style
Jiang HF, Wu Z, Bai X, Zhang Y and He P: Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro. Oncol Lett 8: 1139-1142, 2014.
APA
Jiang, H., Wu, Z., Bai, X., Zhang, Y., & He, P. (2014). Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro. Oncology Letters, 8, 1139-1142. https://doi.org/10.3892/ol.2014.2296
MLA
Jiang, H., Wu, Z., Bai, X., Zhang, Y., He, P."Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro". Oncology Letters 8.3 (2014): 1139-1142.
Chicago
Jiang, H., Wu, Z., Bai, X., Zhang, Y., He, P."Effect of daphnoretin on the proliferation and apoptosis of A549 lung cancer cells in vitro". Oncology Letters 8, no. 3 (2014): 1139-1142. https://doi.org/10.3892/ol.2014.2296
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team